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Abstract: The Janus series of radiation experiments, conducted from 1970 to 1992, 
explored the effects of gamma and neutron radiation on animal lifespan and disease 
development. Data from these experiments presents an opportunity to conduct a large scale 
analysis of both tumor and non-tumor disease development. This work was focused on a 
subset of animals from the Janus series of experiments, comparing acute or fractionated 
exposures of gamma or neutron radiation on the hazards associated with the development 
of tumor and non-tumor diseases of the liver, lung, kidney or vascular system. This study 
also examines how the co-occurrence of non-tumor diseases may affect tumor-associated 
hazards. While exposure to radiation increases the hazard of dying with tumor and  
non-tumor diseases, dose fractionation modulates these hazards, which varies across 
different organ systems. Finally, the effect that concurrent non-cancer diseases have on the 
hazard of dying with a tumor also differs by organ system. These results highlight the 
complexity in the effects of radiation on the liver, lung, kidney and vascular system.  
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1. Introduction 
Epidemiologic studies of radiation exposure on human populations have been limited to  
non-experimental ecological, cohort, and case-control studies. These studies have largely focused on 
radiation workers [1,2], individuals accidentally exposed to radiation through nuclear accidents 
(Chernobyl [3]), or atomic bomb survivors [4]. Because of the retrospective nature of many of these 
studies, dose estimates in human studies are often not exact. Naturally, due to ethical considerations, 
lifetime studies involving experimental, rigorously controlled conditions as well as acute and chronic 
radiation exposures, could only be done with animal models. Thus, the analysis of controlled animal 
data, when considered along-side non-experimental epidemiological studies in humans, may allow for 
a more accurate picture of the effects of radiation on disease.  
Patients exposed to radiation in the medical context are of particular concern, where directed 
radiation treatments of tumors could also result in off-target effects in neighboring tissues. For 
example, the use of radiotherapy in the treatment of breast cancer, typically in combination with the 
surgical excision of the tumor, is common. However, there have been studies suggesting that there 
exists a link between cardiovascular based mortality and morbidity after radiation exposure in patients 
with breast cancer [2]. This is due, presumably, to the proximity of the radiation treatment field to the 
heart and critical veins/arteries. The development of pulmonary diseases have also been associated 
with radiation therapy, particularly radiotherapies directed to the lungs [5]. Radiation pneumonitis is a 
disease which occurs in 5–15% of lung cancer patients who receive radiotherapy [6], and is commonly 
observed in both human and animal models [7]. Other non-tumor diseases, including liver disease [8] 
and renal disease [9] also could be affected by locally administered radiation (either to the liver or to 
the kidney). In addition to non-tumor diseases, secondary tumors can also develop as a consequence of 
radiation therapy [10,11].  
The source of data for this work is the Janus series of radiation biology experiments, a large scale 
study consisting of over 49,000 mice, conducted continuously between 1970 through 1992 [12]. This 
dataset, which is currently hosted at Northwestern University (http://janus.northwestern.edu), is 
publically available, and presents a unique opportunity to explore the effects of radiation on animals 
(at a scale no longer considered feasible by today’s standards) in a controlled environment and under 
experimental conditions with a radiation source that is no longer available. Although some recent 
studies examining the Janus database [13] have aimed to re-discover and preserve this and other large 
scale radiation experiments [14,15], this manuscript is a result of a new effort to re-visit and analyze 
the data on mice exposed to total doses in the range of clinical exposures either acutely or in 60 
fractions. Previous studies using this database either focused on the tumorigenic effects of  
radiation [16,17], or examined pathologies at lower total doses of radiation, comparing frequencies of 
disease between groups of control and irradiated animals [18].  
This analysis was designed to investigate the effect of acute or fractionated exposure of gamma or 
neutron radiation on the hazards associated with the development of non-cancer diseases or cancer in 
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four selected organ systems. In total, 2,785 gamma radiation exposed mice, 1,897 neutron irradiated 
animals and 1,740 controls were selected for this work; of these, 4,797 animals in total developed at 
least one of the diseases of interest. All diseases under investigation were limited to only four organ 
systems: renal, pulmonary, vascular, and liver; the development of tumors as well as the incidence of 
non-tumor diseases was recorded in both genders. These four organ systems have varying levels of 
radiation sensitivity, yet their dysfunction has significant systemic consequences. Additionally, this 
work examines the effect of non-tumor diseases on cancer related life-shortening.  
Ultimately, it is hoped that by examining these issues of cancer and non-tumor related hazards 
using experimental animal data, associations can be found in other data examining risks in humans, 
and thus act as a validation tool for future studies.  
2. Materials and Methods 
2.1. Study Population 
This analysis utilized historical data from the previously described Janus database [14]. Each 
observation in the database was associated with a radiation dose, fractionation, and quality, expressed 
as irradiation codes (specific dose values are also available), lifespan, date of first dose, proctor 
(pathologist) who performed the necropsy, as well as observed pathologies (the probable cause of 
death and accompanying diseases).  
During the course of the Janus experiments, observed gross pathologies were recorded and 
designated as “lethal” or “non-lethal”. Each animal was assigned a single (lethal) probable cause of 
death, but could have multiple additional “non-lethal” pathologies. In this analysis, both “lethal” and 
“non-lethal” variants of a particular pathology were combined, to form an overall pathology outcome 
for each animal. We favored this approach primarily because of the inherent subjectivity in assigning a 
probable cause of death, and that the proctors were under the requirement to assign a single most 
probable cause of death to each animal, thus precluding the possibility of assigning multiple organ 
dysfunction (MODS) as a cause of mortality [19]. Occasionally, a designation of “cause of death 
unknown” was assigned to cases where a probable cause of death could not be ascertained. The latter 
animals were excluded from this analysis because of the possibility that some of the pathologies were 
not recorded in such cases.  
This analysis has used a subset of the entirety of the Janus database, in order to use comparable 
radiation doses across different fractionation patterns. Mice from experiments JM-2 (Janus-2), JM-3, 
and JM-13 were used. Experiments JM-2 and 3 administered single doses of varying levels of gamma 
(90–600 cGy) or neutron radiation (13.5–40 cGy), while in experiment JM-13, mice were irradiated in 
sixty fractions at a closely matched total dose of gamma or neutron radiation. Overall, this analysis 
uses data collected on a total of 6,422 mice; 2,785 mice exposed to gamma radiation, 1,897 exposed to 
neutron radiation, and 1,740 controls sham exposed once or sixty times. All radiation was delivered as 
whole body exposures.  
This analysis used both male and female lab mice (M. musculus), since the outcomes of interest 
involved organ systems that are not sex specific. These were F1 animals from a cross between 
C57BL/6 females and BALB/c males, from parent stocks maintained throughout the twenty years of 
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data accumulation. Control and experimental animals were all kept in a common environment in 
accordance with contemporary animal care protocols over the course of the study.  
2.2. Data Collection 
All mice in this archive were irradiated for the first time at an average age of 112 days (SD: 4.35 
days) using the Janus reactor, a 200 kW uranium fueled reactor. The first experiments were conducted 
in 1972 (JM-2) with continuous experimentation and data collection occurring over a decade, with the 
final animal autopsied in 1984 (JM-13). For mice receiving a fractionated exposure, each fractionated 
dose was given once weekly over sixty weeks; thus, the age difference between animals at the 
conclusion of irradiation amounted to a whole year.  
After irradiation, mice were checked for death twice daily, seven days a week, 365 days per year. 
Necropsies were performed by proctors, both on mice which were found dead and moribund animals 
which were then euthanized. The name of the proctor, as well as accompanying information (i.e., date 
of death, type of radiation used, etc.) were recorded, along with pathology observations. All mice were 
tracked until death (natural death or moribund), with the age at death recorded.  
Since the original Janus experiments grouped recorded gross pathologies by disease types, the same 
designations were used here as well. The pathologies cholecystitis, cirrhosis, and hepatitis were 
grouped under liver diseases. Emphysema, lobar pneumonia, pneumonitis, and pneumonia were 
classified as pulmonary diseases. Myocardium pericardium, and thrombus were classified as 
cardiovascular diseases. Chronic renal disease, hydronephrosis, and polycystic kidney were classified 
as renal diseases. While lung and vascular tumors were each assigned their own group, renal system 
tumors consisted of urinary bladder, kidney, and miscellaneous urogenital tumors (excluding tumors of 
the gonads and reproductive organs), while liver tumors consisted of both liver and gallbladder tumors. 
These eight overall pathology groupings were used as event indicators at the time of death in this 
analysis. Outcomes were binary—either an animal had an observed pathology at death or it did not. 
Mice with non-tumor diseases other than the diseases mentioned above were also included under an 
“other non-tumor disease” outcome, while mice with tumors other than the aforementioned tumors 
were included under the “other tumor” outcome.  
All tissue samples from each mouse were preserved through paraffin embedding—these tissues are 
still available and hosted by Northwestern University, as the Janus Tissue Archive [20]. After 
pathological evaluation, these records were then entered into a database, first hosted on an IBM 
mainframe, then in an Oracle database, and now as a mySQL database hosted at Northwestern 
University (janus.northwestern.edu).  
Over the years, the pathology data in this dataset have been verified via independent audit, with 
over 90% of pathological observations made during the course of each study confirmed through a  
re-evaluation of the preserved tissues [12].  
2.3. Statistical Analysis 
Statistical analyses were performed using R 2.9.2 (www.r-project.org), with a significance level of 
0.05 used throughout the analysis.  
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The following exposures and covariates were examined in this analysis: lifespan (continuous), sex 
(dichotomous), type of radiation dose (categorical: control, gamma, or neutron), total radiation dose 
(continuous), and fractionation (dichotomous: single fraction vs. sixty fractions). Since neutron 
radiation is a densely ionizing radiation, and thus of different quality than gamma radiation at an equal 
dose (Gy), it was determined that neutron and gamma irradiated animals would be stratified into 
separate models.  
The total dose of radiation was characterized as a continuous variable, with discrete values of radiation 
exposure ranging from 90–600 cGy for gamma radiation, and 13.5–40 cGy for neutron radiation. In order 
to better model radiation using both linear and quadratic terms [21], doses were centered around the mean, 
by subtracting the mean gamma or neutron radiation dose from each observation.  
Separate Kaplan-Meier survival curves were generated for animals given either an acute or 
fractionated dose of gamma or neutron radiation. Animals were divided into separate dose groups, with 
animals given the highest (569–600 cGy for gamma, 40 cGy for neutron) or lowest (90–143 cGy for 
gamma, 20–21.5 cGy for neutron) doses analyzed together, while fractionated and acute doses within 
these ranges were matched as closely as possible. Animals given 143 cGy or 90 cGy non-fractionated 
gamma radiation were analyzed with animals given 100 cGy of fractionated gamma radiation to form 
the “lowest” gamma radiation dose group. Animals given 20 cGy of non-fractionated neutron radiation 
were analyzed with animals given 21 cGy of fractionated neutron radiation to form the “lowest” 
neutron radiation dose group. Animals given 569 cGy of non-fractionated gamma radiation were 
analyzed with animals given 600 cGy of fractionated gamma radiation to form the “highest” gamma 
radiation dose group. Finally, animals given 40 cGy of non-fractionated neutron radiation were 
analyzed with animals given 40 cGy of fractionated neutron radiation to form the “highest” neutron 
radiation dose group (to ensure the validity of grouping animals with similar total doses within a 
fractionation pattern, groupings were determined by log-rank tests of survival—doses of the same 
fractionation pattern were grouped only if there were no significant differences in survival). These KM 
curves used survival times for animals which died with the specific disease of interest. Animals were 
censored if an animal died with a disease other than the disease being studied. These curves show the 
difference in survival associated with having a particular disease, comparing animals given a 
fractionated radiation dose to a non-fractionated dose at a closely matched total dose. 
Additionally, Cox proportional hazards regressions were run examining the effect of radiation on 
the hazard of dying with renal, liver, cardiovascular, or pulmonary disease (non-tumor diseases) or a 
renal system, liver, vascular, or lung tumor (cancer-diseases). These models were stratified by dose 
fractionation pattern—separate models were generated using animals given either an acute or 
fractionated radiation dose. The radiation dose was initially assumed to have a linear-quadratic 
relationship with hazard, but in cases where the quadratic term was found to be non-significant, only 
the linear term was included. The use of a simple linear radiation dose term to describe life-shortening 
was found to be sufficient in previous studies which compared multiple models [16,22]. Due to 
differences in the range of doses between gamma and neutron radiation models, gamma radiation 
doses which were originally in cGy were expressed in Gy, while in neutron radiation models, cGy was 
converted to 10 cGy “units” (i.e., a one unit increase in neutron radiation dose can be interpreted as a 
10 cGy increase). This was done in order to generate more easily interpretable regression coefficients. 
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Dichotomous variables for both cancer and non-tumor disease were used as the event indicators. Sex 
was used as a (dichotomous) covariate in the adjusted regressions.  
Lastly, to examine the association between non-tumor and tumor disease at the time of death, 
hazards were estimated using sex adjusted, fractionation-stratified Cox regressions (using each cancer 
endpoint as an event indicator and the presence of each non-tumor disease as a dichotomous variable). 
Evaluation of the violation of the proportional hazards assumption for each Cox model was performed 
in R via a test for a non-zero slope in the regression of time on scaled Schoenfeld residuals [23].  
3. Results 
Table 1 presents an excerpt of the Janus dataset which was used in this study, with overall and 
stratified counts/percentages. The data used in this study were: (1) animals acutely exposed to total 
dose exposures close to the doses used in a clinical setting, (2) the animals that received a closely 
matched total dose in 60 weekly fractions and (3) the sham irradiated controls.  
Table 1. Data summary.  
 Total Gamma Neutron Control 
Total # 6,422 2,785 1,897 1,740 
Sex % (#)     
Male 55.33 (3,553) 57.70 (1,607) 55.35 (1,050) 51.49 (896) 
Female 44.67 (2,869) 42.30 (1,178) 44.65 (847) 48.51 (844) 
Fractions % (#)     
1 35.57 (2,284) 34.94 (973) 32.47 (616) 39.94 (695) 
60 64.43 (4,138) 65.06 (1,812) 67.52 (1,281) 59.77 (1,045) 
     
Lifespan days (mean, sd) (934.69, 194.26) (923.99, 198.52) (909.49, 187.83) (979.28, 186.83) 
Non-tumor Outcomes % (#)     
Renal  8.08 (519) 6.64 (185) 6.75 (128) 11.84 (206) 
Liver 1.12 (77) 1.18 (33) 1.32 (25) 1.09 (19) 
(Cardio)vascular 0.965 (62) 0.90 (25) 0.63 (12) 1.44 (25) 
Pulmonary 40.52 (2,602) 40.40 (1,125) 39.69 (753) 41.61 (724) 
Other 60 (3,851) 59.93 (1,669) 58.46 (1,109) 61.67 (1,073) 
Cancer (tumor) Outcomes % (#)     
Renal 1.46 (94) 0.90 (25) 3.22 (61) 0.46 (8) 
Liver 5.34 (343) 4.78 (133) 6.59 (125) 4.89 (85) 
Vascular  8.44 (543) 9.05 (252) 9.07 (172)  6.78 (118) 
Pulmonary  42.34 (2,719)  41.62 (1,159) 42.49 (806)  43.33 (754) 
Other 68.84 (4,421) 70.34 (1,959) 67.84 (1,287) 67.53 (1,175) 
Baseline characteristics and outcomes of Janus experiments 2, 3, and 13—stratified by radiation quality. 
Values within parentheses for lifespan measures indicate the mean and standard deviation, while the 
remaining values are percentages indicating the proportion of cases in that particular treatment group. Values 
in parentheses are counts of cases. 
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The total doses under consideration were from 0.9 to 6 Gy for gamma rays or 0.135 to 0.4 Gy for 
neutron doses. These ranges were selected due to the RBE for fission spectrum neutrons used in the 
Janus experiments, which was believed to be at least equal to 10 [12].  
The distribution of subjects across treatment groups varied when compared using sex and 
fractionation pattern, with males (N = 3,553) outnumbering females (N = 2,869). With respect to 
fractionation pattern, 2,284 animals were given a single treatment compared to 4,138 animals given a 
fractionated irradiation or sham-irradiation.  
Using the animals selected in Table 1, Kaplan-Meier (KM) survival curves focusing on the cancer 
and non-cancer diseases of the four organ systems also presented in Table 1 were constructed. These 
KM survival curves compared mice which received an acute dose of radiation, compared to mice 
which received a closely matched fractionated dose. These results are presented in Figures 1 and 2. 
Figure 1(a) presents animals given 569–600 cGy of gamma radiation, using the presence of each 
disease or tumor at death as an event indicator. While it was difficult to interpret some of the results 
with low event counts, e.g., incidences of kidney, liver, or cardiovascular disease for animals given a 
fractionated dose, the general trend is that animals given a fractionated dose had a significantly lower 
hazard of having lung tumors, vascular tumors, and liver tumors at the time of death, compared to 
animals given a single radiation dose. This trend was also observed in the non-tumor diseases, with the 
exception of pulmonary disease. While these trends were again observed at the lowest range of gamma 
radiation doses (90–143 cGy gamma rays), the difference in life shortening related to pulmonary 
disease between fractionated and single exposures becomes significant, and interestingly, reversed—at 
90–143 cGy gamma radiation, dose fractionation is associated with an increased hazard of dying with 
pulmonary disease.  
Figure 2(a,b) present Kaplan-Meier survival curves in animals given neutron radiation. As was 
observed in the animals exposed to gamma radiation, low counts of events in animals for a number of 
disease outcomes affected the analysis. However, mice exposed to fractionated doses had a higher 
hazard associated with pulmonary disease development compared to their acute exposure counterparts 
for both the highest and lowest neutron radiation treated animals, while the opposite was observed in 
the survival curves examining kidney related tumor and disease, particularly at the lowest neutron 
radiation dose.  
To test how gamma radiation and fractionation affect the hazard of dying with either a tumor or 
non-tumor disease, Cox proportional hazards regressions were generated. Table 2 presents adjusted (by 
sex) and unadjusted estimated hazard ratios examining gamma radiation, stratified by fractionation, 
and separated by organ system and further by tumor/non-tumor disease. The presented values are the 
estimated hazard ratios for radiation dose. Significant hazard ratios for the linear form of these 
regressions were found for many adjusted and unadjusted tumor models. It is important to note that a 
direct comparison in hazard ratios across fractionation patterns should not be made, since both 
fractionation patterns have varying underlying hazard functions. One can only examine increases in 
hazard in response to dose, relative to each fractionation pattern. For example, in the adjusted models, 
for each 1 Gy increase in gamma radiation total dose, the relative increase in the hazard of dying with 
a vascular tumor was 19% for fractionated exposures, while the relative increase in hazard was 22% 
for acute exposures. Thus, the relative effect of increasing gamma radiation dose on the hazard of 
dying with a vascular tumor varied between mice given fractionated or acute irradiation. 
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Figure 1. Gamma radiation survival curves.  
 
Kaplan-Meier curves of animals having a disease or tumor in the organ systems of interest at the time of 
death, following acute (solid line) or fractionated (dotted line) gamma irradiation in the dose ranges 
indicated. All p-values correspond to the log-rank test to determine differences between fractionation status 
survival curves. (a) Survival curves corresponding to animals given the highest (569–600 cGy) gamma 
radiation. (b) Survival curves corresponding to animals given the lowest (90–143 cGy) gamma radiation. 
Censored observations were not marked in the graphs, to aid in distinguishing between the two curves, but 
were present in the analysis. Censored observations were animals which died from a disease other than the 
analyzed disease.  
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Figure 2. Neutron radiation survival curves.  
 
Kaplan-Meier curves of animals that developed a disease or tumor in either of the four organ systems under 
investigation at the time of death, following acute (solid line) or fractionated (dotted line) neutron irradiation 
in the total doses as indicated. All p-values correspond to the log-rank test to determine differences between 
survival curves. Censored observations were not marked in the graphs, to aid in distinguishing between the 
two curves, but were present in the analysis. Censored observations were animals which died from a disease 
other than the analyzed disease.  
 
In the adjusted models for renal system tumor related hazard, only the animals irradiated with a single 
dose had a significant hazard ratio, with a 1 Gy increase in gamma radiation dose corresponding to a  
70% increase in renal system tumor related hazard. Interestingly, the relative increase in the hazard of 
dying with a lung tumor for a 1 Gy increase in gamma radiation was at 15% in animals exposed to 60 
weekly fractions, while this increase was at 11% in animals given a single radiation dose. No significant 
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quadratic relationships were found between tumor related hazard and dose. There were fewer significant 
hazards of non-tumor diseases, and therefore fewer differences across fractionation groups. For example, 
the liver disease related hazard was significantly increased (by 34% in the adjusted model) in animals 
given a single dose, while a 13% increase in lung disease related hazard was observed in animals given 
fractionated irradiation. Interestingly, a significant quadratic relationship was observed between kidney 
disease related hazard and dose, but only in the un-adjusted model.  
Table 2. Risk of organ system pathologies, gamma radiation.  
Organ Model Fractions 
Tumor Non-tumor Disease 
Linear Quadratic Linear Quadratic 
HR (95% Conf. Int) HR (95% Conf. Int) HR (95% Conf. Int) HR (95% Conf. Int) 
Kidney  
(renal) 
Adj. 60 1.11 (0.798, 1.56) - 1.00 (0.874, 1.15) - 
1 1.71 (1.36, 2.17) - 0.931 (0.797, 1.09) * 1.07 (1.01, 1.13) * 
Unadj. 60 1.11 (0.80, 1.56) - 0.987 (0.859, 1.13) - 
1 1.73 (1.38, 2.18) * - 0.722 (0.626, 0.834) 1.15 (1.09, 1.22) 
Liver 
Adj. 60 1.03 (0.899, 1.19) - 0.846 (0.552, 1.30) - 
1 1.40 (1.27, 1.55) - 1.34 (1.10, 1.62) - 
Unadj. 60 1.04 (0.90, 1.20) - 0.846 (0.551, 1.30) - 
1 1.39 (1.26, 1.55) - 1.37 (1.13, 1.65) - 
Vascular  
(cardio) 
Adj. 60 1.19 (1.11, 1.28) - 0.941 (0.675, 1.31) * - 
1 1.22 (1.12, 1.35) - 0.674 (0.397, 1.14) 1.3 (1.09, 1.56) 
Unadj. 60 1.19 (1.10, 1.29) - 0.95 (0.68, 1.32) - 
1 1.23 (1.12, 1.35) - 0.697 (0.413, 1.17) 1.29 (1.08, 1.54) 
Lung  
(pulmn.) 
Adj. 60 1.15 (1.12, 1.20) - 1.13 (1.09, 1.17) - 
1 1.11 (1.07, 1.17) - 1.04 (0.944, 1.14) 1.05 (1.02, 1.09) 
Unadj. 60 1.16 (1.12, 1.21) - 1.12 (1.09, 1.16) - 
1 1.13 (1.09, 1.19) - 1.17 (1.11, 1.23) 1.06 (1.02, 1.09) 
Table of Cox regression hazard ratios (corresponding to the gamma radiation dose term) and accompanying 
95% confidence intervals in gamma radiation models. Values in bold indicate significant hazard ratios at the 
5% level. Models with non-significant quadratic terms were fit using only the linear term, and those estimates 
are presented here. Quadratic HR estimates are presented only for models in which there was a significant 
quadratic term. * indicates that the particular model did not satisfy the proportional hazards assumption.  
We next tested how neutron radiation and fractionation affected the hazard of dying with a 
tumor/non-tumor disease. Table 3 presents sex adjusted and unadjusted estimated hazard ratios 
examining neutron radiation, stratified by fractionation, and separated by organ system and then by 
tumor/disease. Significant hazard ratios for the linear components of these regressions were found for 
nearly all adjusted and unadjusted tumor models. For example, in the adjusted models, for a 0.01 Gy 
increase in neutron radiation dose, the relative increase in the hazard of dying with a renal system 
tumor was 96% in animals given sixty fractions, while the relative increase in hazard was 375% in 
animals given a single dose. A number of non-tumor diseases were also found to be significantly 
associated with the linear component of total radiation dose. For example, with a 0.01 Gy increase in 
neutron radiation dose, there was a 24% increase in the hazard of dying with a renal disease (in the 
fractionated irradiation, adjusted model), a 43% increase in liver disease associated hazard (in the 
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acute irradiation, adjusted model), and a 19% increase in pulmonary disease associated hazard (in the 
fractionated irradiation, adjusted model).  
Table 3. Risk of organ system pathologies, neutron radiation.  
Organ Model Fractions 
Tumor Non-tumor Disease 
Linear Quadratic Linear Quadratic 
HR (95% Conf. Int) HR (95% Conf. Int) HR (95% Conf. Int) HR (95% Conf. Int) 
Kidney  
(renal) 
Adj. 60 1.96 (1.45, 2.66) - 1.24 (1.05, 1.45) - 
1 3.75 (2.19, 6.42) 0.782 (0.634, 0.965) 1.02 (0.896, 1.15) 1.11 (1.00, 1.23) 
Unadj. 60 1.98 (1.47, 2.69) - 1.18 (1.01, 1.39) - 
1 3.67 (2.15, 6.27) 0.769 (0.626, 0.946) 0.892 (0.800, 0.993) - 
Liver 
Adj. 60 1.40 (1.22, 1.60) - 1.10 (0.767, 1.58) - 
1 1.24 (1.07, 1.44) - 1.43 (1.07, 1.91) - 
Unadj. 60 1.41 (1.23, 1.61) - 1.09 (0.762, 1.56) - 
1 1.24 (1.08, 1.43) - 1.45 (1.10, 1.89) - 
Vascular  
(cardio) 
Adj. 60 1.24 (1.12, 1.38) - 0.753 (0.469, 1.21) - 
1 1.30 (1.11, 1.52) - 1.05 (0.746, 1.49) - 
Unadj. 60 1.25 (1.13, 1.39) - 0.747 (0.466, 1.20) - 
1 1.21 (1.05, 1.39) - 1.09 (0.782, 1.54) - 
Lung  
(pulmn.) 
Adj. 60 1.23 (1.17, 1.30) * - 1.19 (1.14, 1.25) - 
1 1.05 (0.993, 1.11) - 0.992 (0.919, 1.07) * - 
Unadj. 60 1.25 (1.19, 1.32) - 1.19 (1.13, 1.24) - 
1 1.09 (1.03, 1.15) - 0.983 (0.913, 1.06) * - 
Table of Cox regression hazard ratios (corresponding to the neutron radiation dose term) and accompanying 
95% confidence intervals in neutron radiation models. Bolded values indicate significant hazard ratios at the 
5% level. Models with non-significant quadratic terms were fit using only the linear term, and those estimates 
are presented here. Quadratic HR estimates are presented only for models in which there was a significant 
quadratic term.* indicates that the particular model did not satisfy the proportional hazards assumption.  
Next, we examined how the presence of a non-tumor disease affects the risk of dying with a tumor 
following acute or fractionated irradiation. Table 4 presents estimated hazard ratios of dying with both 
a tumor and a non-tumor disease, adjusted for total dose, sex, and stratified by fractionation. Both 
positive and negative associations were found. In the models where animals were given fractionated 
gamma radiation, the relative decrease in the hazard of dying with a lung tumor with concomitant 
cardiovascular disease was ~70% compared to animals without cardiovascular disease, while the 
relative decrease in hazard(with the same conditions) for acutely irradiated mice was ~55%. The 
hazard of dying with a vascular tumor and a renal disease decreased by ~64% in animals given a 
fractionated radiation dose, compared to animals without a renal disease, while a relative decrease of 
~46% was found in animals given a single dose of radiation. Similarly, among animals given sixty 
fractions, there was a ~61% decrease in the hazard of dying with a vascular tumor and a pulmonary 
disease compared to mice without a pulmonary disease, while the relative decrease in hazard was  
~41% in animals given a single fraction. 
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In animals given neutron radiation, a ~39% decrease in the hazard of dying with a lung tumor and a 
renal disease was observed in animals given a fractionated dose, compared to animals which died with 
a lung tumor without renal disease, while a relative decrease in hazard of 42% was found in animals 
given a single dose. Other disease models with a significant decrease in the hazard of co-occurrence 
after neutron exposure were the pairs (i) pulmonary disease and renal system tumor hazard,  
(ii) pulmonary disease and liver tumor hazard, (iii) renal disease and vascular tumor hazard, and  
(iv) pulmonary disease and vascular tumor hazard (Table 4). Unsurprisingly, in the models where 
animals were given either qualities of radiation, pulmonary disease was significantly associated with 
an increase in the hazard of dying with a lung tumor, across both fractionation patterns. 
Table 4. The effect of disease on tumor risk.  
Tumor Disease 
Gamma Neutron 
Fractionated Non-Fractionated Fractionated Non-Fractionated 
HR (95% Conf. Int) HR (95% Conf. Int) HR (95% Conf. Int) HR (95% Conf. Int) 
Kidney 
(renal) 
Renal  - 1.50 (0.473, 4.74) 0.539 (0.072, 4.04) 0.603 (0.235, 1.55) 
Liver - - - 0.459 (0.063, 3.35) 
Cardio (vascular) - 2.58 (0.332, 20.1) - 1.31 (0.179, 9.62) 
Pulmonary 0.184 (0.0415, 0.819) 0.703 (0.230, 2.14) 0.238 (0.080, 0.705) 1.13 (0.572, 2.25) 
Liver 
Renal 0.370 (0.0904, 1.51) 0.682 (0.401, 1.16) 0.570 (0.231, 1.41) 0.610 (0.340, 1.09) 
Liver 1.82 (0.253, 13.09) 0.587 (0.144, 2.39) 0.782 (0.109, 5.63) 0.557 (0.138, 2.27) 
Cardio (vascular) 1.13 (0.276, 4.61) 0.968 (0.238, 3.93) 0.752 (0.104, 5.42) 1.54 (0.378, 6.25) 
Pulmonary 0.820 (0.552, 1.22) 0.910 (0.60, 1.38) 0.566 (0.382, 0.839) 1.29 (0.830, 2.02) 
Vascular 
(cardio) 
Renal 0.358 (0.132, 0.967) 0.533 (0.312, 0.912) 0.164 (0.0405, 0.662) 1.08 (0.670, 1.74) 
Liver 0.926 (0.130, 6.61) 0.458 (0.113, 1.86) NA 0.650 (0.160, 2.65) 
Cardio (vascular) 1.05(0.336, 3.31) 0.390 (0.0541, 2.77) 0.971 (0.240, 3.93) 0.808 (0.112, 5.81) 
Pulmonary 0.389 (0.288, 0.525) 0.586 (0.385, 0.892) 0.400 (0.289, 0.554) 0.415 (0.230, 0.746) 
Lung 
(pulmn.) 
Renal 0.919 (0.674, 1.25) 0.608 (0.492, 0.751) 0.612 (0.437, 0.857) 0.577 (0.460, 0.725) 
Liver 0.584 (0.188, 1.82) 0.802 (0.527, 1.22) 0.576 (0.258, 1.29) 0.595 (0.349, 1.01) 
Cardio (vascular) 0.301 (0.125, 0.726) 0.448 (0.213, 0.944) 0.501 (0.224, 1.12) 0.523 (0.217, 1.26) 
Pulmonary 1.15 (1.02, 1.30) 1.55 (1.35, 1.79) * 1.15 (1.00, 1.31) 1.75 (1.50, 2.04) * 
Table of Cox regression hazard ratios and accompanying 95% confidence intervals in gamma and neutron 
radiation models corresponding to the estimated hazard ratio of the disease of interest. Models used to obtain 
these estimated HR coefficients used a linear dose term only, due to the lack of a significant quadratic dose 
term in the previous cancer based models. Bolded values indicate significant hazard ratios at the 5% level.  
* indicates that the particular model did not satisfy the proportional hazards assumption. 
4. Discussion 
With such a large and comprehensively documented database of controlled radiobiology 
experiments, the Janus series of experiments presents a rare opportunity to evaluate the pathological 
effects of radiation on animals. This manuscript examined the effects of both gamma and neutron 
irradiation on a set of well characterized biological endpoints: lung, vascular, liver, and renal system 
Int. J. Environ. Res. Public Health 2012, 9 4700 
 
cancers and non-tumor pathologies of the same four organ systems (pulmonary, cardiovascular, liver, 
and renal disease). We also sought to analyze the effects of dose fractionation on these endpoints, and 
the association between non-tumor diseases and tumor associated hazard.  
This work shows that fractionation plays a significant role in both tumor and non-tumor disease 
related hazard, in both gamma and neutron irradiated animals. Kaplan-Meier curves presented in 
Figures 1 and 2 indicated that fractionation was significantly associated with a longer survival across 
multiple diseases and tumors. The only exception was pulmonary disease, found in mice dying at 
earlier ages following fractionated exposure to either gamma rays or neutron radiation. This was found 
in mice exposed to both the highest and the lowest doses of neutron radiation, and only for the lowest 
doses of gamma rays (while the difference between KM survival curves of animals dying with 
pulmonary disease at the highest gamma radiation dose was not significant). Further, this relationship 
was not seen in the survival curves of mice with lung tumors. In these mice, fractionated gamma 
radiation was associated with pulmonary cancer occurrence in longer living animals than in their 
acutely exposed counterparts. While it was expected that the hazard of dying with a lung tumor would 
be lower in animals given a fractionated radiation dose, it was unexpected that the same relationship 
was not observed in animals dying with a non-tumor pulmonary disease. Because a correlation 
between the development of lung tumors and pulmonary disease (particularly pneumonitis) has been 
observed in humans [24] this result is indicative of the complexities of tumor formation and disease 
progression in response to total radiation dose and dose fractionation.  
Secondly, increases in total gamma and neutron radiation dose were both significantly associated 
with a higher hazard of having a tumor at the time of death, while the hazard of dying with a  
non-tumor disease was found to be significantly associated with increasing radiation exposure for only 
a few non-tumor diseases. This confirms the linear-dose response of tumor expression at the time of 
death for both gamma and neutron radiation [16]. More interesting, however, was of the relative lack 
of association between increasing radiation dose and non-tumor disease related hazard. For example, 
while the hazard of dying with a pulmonary disease was significantly increased as radiation dose was 
escalated (across both gamma and neutron radiation groups), a similar increase was observed only in 
certain liver and kidney related hazard models. A likely explanation for this observation is that many 
of these animals may have died from a cancer based disease before they had a chance to develop a 
non-tumor disease. Indeed, previous studies examining the Janus database have observed that 
roughly 85% of animals died from a neoplastic disease [16,25]. The effect of radiation on the hazard 
of dying with a non-tumor disease may be obscured by the large number of animals that died earlier 
due to a tumor.  
Thirdly, dose fractionation (both gamma and neutron radiation) had different relative effects on 
hazard across the different pathologies, with some pathology models (e.g., vascular tumors) having an 
increase in relative hazard when moving from non-fractionated to fractionated radiation, as the total 
radiation dose was escalated. Meanwhile, other pathologies (e.g., lung tumors) had a decrease in 
relative hazard, when moving from non-fractionated to fractionated radiation, as the total dose 
increased. While the baseline hazards varied between fractionated and non-fractionated animals, these 
relative changes in hazard in response to increased radiation reflect the varied effect that fractionation 
might have on a particular organ system. For example, in animals given sixty weekly fractions of 
neutron radiation, the hazard of a 0.01 Gy increase resulted in a 96% increase in the hazard of dying 
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with a renal system tumor, while in acutely exposed animals, the dose-hazard relationship was found 
to be linear-quadratic, with the increase in hazard (from the linear component of the regression) found 
to be by 375%. This trend was reversed for the hazard of dying with a lung tumor, in both gamma and 
neutron irradiated animals. This varied response to dose fractionation again reflects the significant 
differences in the survival of animals afflicted by tumors of different organ systems. The lungs are 
particularly sensitive to dose fractionation, with radiation considered to primarily affect pulmonary 
endothelial cells [5]. These differences in the response to dose fractionation may also be indicative of the 
comparative radiosensitivity and rate of cellular turnover of the lung compared to the kidney or liver.  
Fourth, the simultaneous occurrence of non-tumor diseases with a tumor was significantly 
associated with changes in tumor related hazard, while again, these relative changes in hazard varied 
between models where animals were exposed to fractionated and non-fractionated irradiation. In Table 4, 
the presence of a pulmonary disease is significantly associated with an increased hazard of dying with 
a lung tumor, compared to animals without a pulmonary disease. However, the tumor related hazards 
of all other organ systems—kidney, liver, and vascular, decreased when in the presence of a variety of 
non-tumor diseases. This suggests that pathologies of the lung organ system (tumor and non-tumor 
disease) are inter-dependent on each other, an interdependence that is not observed in other organ 
systems. Further, relative decreases in hazard also varied across fractionation groups, indicating that 
fractionation also plays an important role in modulating the association between a particular disease 
and a particular tumor.  
This study has a number of caveats. First, since this analysis used animal data, the extrapolation of 
predictions to human subjects may be difficult. While previous studies have shown the usefulness of 
this Janus dataset in making cross-species predictions [25,26] more work must be done in determining 
which diseases may be comparable between species, with future studies focusing on Janus 
experimental data in larger mammals (dogs [26,27]), data which is also now publically available. 
Second, since this analysis included data from three experiments, it can be expected that the expansion 
of this analysis through the addition of other JM experiments could allow for more robust regression 
models, although the experiments (and doses) considered here were carefully selected to ensure close 
matches across fractionation patterns.  
Ultimately, while this investigation confirmed that increased radiation indeed is associated with an 
increased hazard of dying with cancer, it has also shown that radiation plays an important role in the 
hazards associated with dying with a non-tumor disease. Further, dose fractionation strongly modulates 
the effect of radiation on these hazards. Finally, the co-occurrence of a non-tumor disease can also 
affect the hazards associated with dying with a tumor, but varies across organ systems. The ability to 
examine these radiobiology questions in animals, using the data generated through a series of carefully 
controlled experiments, is a rare opportunity, and it is hoped that this work will further promote the use 
and analysis of the Janus database as a unique and valuable radiobiology resource.  
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